NRX Pharmaceuticals Valuation
| NRXP Stock | USD 2.27 0.02 0.87% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. NRX Pharmaceuticals secures a last-minute Real Value of $9.6 per share. The latest price of the firm is $2.27. Our model forecasts the value of NRX Pharmaceuticals from reviewing the firm fundamentals such as Return On Asset of -1.46, current valuation of 43.46 M, and Return On Equity of -6.83 as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that NRX Pharmaceuticals' price fluctuation is risky at this time. Calculation of the real value of NRX Pharmaceuticals is based on 3 months time horizon. Increasing NRX Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
NRX Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 2.27, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.27 | Real 9.6 | Hype 3.14 | Naive 2.48 |
The intrinsic value of NRX Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NRX Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NRX Pharmaceuticals helps investors to forecast how NRX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NRX Pharmaceuticals more accurately as focusing exclusively on NRX Pharmaceuticals' fundamentals will not take into account other important factors: NRX Pharmaceuticals Total Value Analysis
NRX Pharmaceuticals is now anticipated to have valuation of 43.46 M with market capitalization of 38.4 M, debt of 9.16 M, and cash on hands of 24.55 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the NRX Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
43.46 M | 38.4 M | 9.16 M | 24.55 M |
NRX Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of NRX is to check how much profit was generated for every dollar of assets it reports. NRX Pharmaceuticals secures a negative usage of assets of -1.46 %, losing $0.0146 for each dollar of assets held by the firm. Unsuccessful asset utilization conveys that the company is being less efficient with each dollar of assets it secures. Strictly speaking, asset utilization of NRX Pharmaceuticals shows how unproductive it operates for each dollar spent on its assets.NRX Pharmaceuticals Ownership Allocation
NRX Pharmaceuticals maintains a total of 16.92 Million outstanding shares. NRX Pharmaceuticals secures 16.37 % of its outstanding shares held by insiders and 5.94 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NRX Pharmaceuticals Profitability Analysis
Net Loss for the year was (30.15 M) with profit before overhead, payroll, taxes, and interest of 0.About NRX Pharmaceuticals Valuation
The stock valuation mechanism determines NRX Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of NRX Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of NRX Pharmaceuticals. We calculate exposure to NRX Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NRX Pharmaceuticals's related companies.NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
NRX Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as NRX Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 7.6 M |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.